Unlearn.AI

What is Unlearn.AI?

Unlearn.AI transforms clinical development by generating digital twins-virtual replicas of trial participants-that enable more efficient and accurate clinical trials. This approach reduces the need for large control groups, accelerates trial timelines, and enhances statistical power without increasing participant numbers. The platform supports diverse stakeholders from biotechs to large pharmaceutical companies by integrating seamlessly with existing infrastructures and maintaining strict data privacy and regulatory compliance. Unlearn.AI’s technology is recognized by regulatory bodies and is advancing clinical trials in neurological and other therapeutic areas.

Key Features

• Digital Twins Technology

  Creates virtual models of trial participants to simulate clinical outcomes across all future time points, reducing reliance on large control arms.

• Trial Efficiency and Cost Reduction

  Enables smaller, faster trials by improving statistical power and reducing patient enrollment needs, leading to significant cost savings.

• Regulatory Alignment

  Methods qualified by the European Medicines Agency and aligned with FDA guidance to support pivotal phase 3 trials.

• Flexible Integration

  Works with diverse clinical trial infrastructures and data environments, ensuring secure data handling and easy adoption.

• Stakeholder Support

  Tailors solutions for biotechs, small-mid pharma, and large pharma to meet their unique challenges in clinical development.

Use Cases

• Accelerating Clinical Trials : Speeds up trial timelines by reducing patient recruitment needs and enhancing early decision-making.
• Enhancing Trial Design : Optimizes sample sizes and statistical power through AI-driven simulations, improving trial feasibility and outcomes.
• Supporting Neurological Research : Applied in trials for diseases like ALS and Alzheimer’s to improve efficiency and confidence in results.
• Reducing Development Costs : Lowers overall clinical trial expenses by minimizing control group sizes and shortening study durations.
• Regulatory-Ready Clinical Evidence : Generates data compliant with regulatory standards to support drug approval processes.

FAQs